1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis - Drugs In Development, 2022, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Sinusitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 6, 7, 3, 14, 2 and 1 respectively.
Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sinusitis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sinusitis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sinusitis (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sinusitis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Sinusitis - Overview
- Sinusitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Sinusitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Sinusitis - Companies Involved in Therapeutics Development
- Sinusitis - Drug Profiles
- Sinusitis - Dormant Projects
- Sinusitis - Discontinued Products
- Sinusitis - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Sinusitis, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Sinusitis - Pipeline by 3SBio Inc, 2022
- Sinusitis - Pipeline by Amgen Inc, 2022
- Sinusitis - Pipeline by Amytrx Therapeutics Inc, 2022
- Sinusitis - Pipeline by AnaptysBio Inc, 2022
- Sinusitis - Pipeline by Aodh Lifesciences Pvt Ltd, 2022
- Sinusitis - Pipeline by Argenx SE, 2022
- Sinusitis - Pipeline by Beijing FuKangren Bio-pharm Tech Co Ltd, 2022
- Sinusitis - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
- Sinusitis - Pipeline by Furen Pharmaceutical Group Co Ltd, 2022
- Sinusitis - Pipeline by GeneOne Life Science Inc, 2022
- Sinusitis - Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022
- Sinusitis - Pipeline by GlycoMira Therapeutics Inc, 2022
- Sinusitis - Pipeline by GSK plc, 2022
- Sinusitis - Pipeline by Insmed Inc, 2022
- Sinusitis - Pipeline by IVIEW Therapeutics Inc, 2022
- Sinusitis - Pipeline by Jantar GmbH, 2022
- Sinusitis - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2022
- Sinusitis - Pipeline by KeyMed Biosciences Inc, 2022
- Sinusitis - Pipeline by Kyowa Kirin Co Ltd, 2022
- Sinusitis - Pipeline by Lanier Biotherapeutics Inc, 2022
- Sinusitis - Pipeline by Lyra Therapeutics Inc, 2022
- Sinusitis - Pipeline by Maxwell Biosciences Inc, 2022
- Sinusitis - Pipeline by Merck & Co Inc, 2022
- Sinusitis - Pipeline by Nexeos Bio, 2022
- Sinusitis - Pipeline by Nota Laboratories LLC, 2022
- Sinusitis - Pipeline by OptiNose Inc, 2022
- Sinusitis - Pipeline by Oticara Inc, 2022
- Sinusitis - Pipeline by Pfizer Inc, 2022
- Sinusitis - Pipeline by ProclaRx LLC, 2022
- Sinusitis - Pipeline by Quorum Innovations LLC, 2022
- Sinusitis - Pipeline by RAPT Therapeutics Inc, 2022
- Sinusitis - Pipeline by Recce Pharmaceuticals Ltd, 2022
- Sinusitis - Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Sinusitis - Pipeline by SaNOtize Research and Development Corp, 2022
- Sinusitis - Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
- Sinusitis - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022
- Sinusitis - Pipeline by Synermore Biologics Co Ltd, 2022
- Sinusitis - Pipeline by Trellis Bioscience Inc, 2022
- Sinusitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2022
- Sinusitis - Dormant Projects, 2022
- Sinusitis - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Sinusitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Amgen Inc
- Amytrx Therapeutics Inc
- AnaptysBio Inc
- Aodh Lifesciences Pvt Ltd
- Argenx SE
- Beijing FuKangren Bio-pharm Tech Co Ltd
- Biohaven Pharmaceutical Holding Company Ltd
- Furen Pharmaceutical Group Co Ltd
- GeneOne Life Science Inc
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- GlycoMira Therapeutics Inc
- GSK plc
- Insmed Inc
- IVIEW Therapeutics Inc
- Jantar GmbH
- JiangSu Qyuns Therapeutics Co Ltd
- KeyMed Biosciences Inc
- Kyowa Kirin Co Ltd
- Lanier Biotherapeutics Inc
- Lyra Therapeutics Inc
- Maxwell Biosciences Inc
- Merck & Co Inc
- Nexeos Bio
- Nota Laboratories LLC
- OptiNose Inc
- Oticara Inc
- Pfizer Inc
- ProclaRx LLC
- Quorum Innovations LLC
- RAPT Therapeutics Inc
- Recce Pharmaceuticals Ltd
- Regeneron Pharmaceuticals Inc
- SaNOtize Research and Development Corp
- Shandong Boan Biotechnology Co Ltd
- Suzhou Connect Biopharmaceuticals Ltd
- Synermore Biologics Co Ltd
- Trellis Bioscience Inc
- Wuhan Yicheng Biotechnology Co Ltd
